摘要:
Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
摘要:
Compounds (III) active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
摘要:
Compounds are described that are active on at least one of PPARα, PPARδ, and PPARϜ, which are useful for therapeutic and /or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARϜ.
摘要:
Compounds are described that are active on PDE4. Also described are crystal structures of PDE4B determined using X-ray crystallography, the use of PDE4B crystals and stractural information for identifying molecular scaffolds, for developing ligands that bind to and modulate PDE4B, and for identifying improved ligands based on known ligands.
摘要:
Compounds with 7-azaindole core structure with activity toward the receptor protein tyrosine kinase c-kit, compositions useful for treatment c-kit-mediate diseases or conditions, and methods of use thereof, are provided. Further provided are methods of c kit ligand identification and design.
摘要:
The present disclosure provides a process for the preparation of crystalline Form C of Compound II:
comprising: (1) adding Compound II to from about 0.4% v/v wet methyl tert-butyl ether (MTBE) to about 1.5% v/v wet MTBE to provide a reaction mixture; (2) refluxing the reaction mixture; (3) cooling the reaction mixture to about room temperature; and (4) isolating the crystalline Form C of Compound II from the reaction mixture.